Pharming receives subsidies for research in osteoporosis.

(From Chemical Business NewsBase - Press Release)

Biotech company Pharming Group NV announced that its wholly owned subsidiary DNage has been granted two SenterNovem subsidies totalling just over EUR 1 M, over a period of three years, to develop products in the field of osteoporosis. The granting of these subsidies exemplifies Pharming's strategy to expand its research engine and to strengthen its product pipeline. Several early stage programmes have already been initiated at Pharming/DNage and partnered with academic institutions and biotech companies. The company has started to finance these programmes through national and European subsidy programmes. Under a …